Are Testosterone Pellets FDA Approved? What to Check Before You Consent

Are testosterone pellets FDA approved?

Some testosterone pellets are FDA-approved and some are not, so a plain yes or no is misleading. Testopel is an FDA-approved 75 mg testosterone pellet whose label lists male indications only. Pellets compounded for women in menopause clinics are not FDA-approved finished products. No testosterone product is FDA-approved for women in the United States.

The confusion isn’t your fault. It’s built into the question. “Are testosterone pellets FDA approved” is actually four questions wearing one coat. Most pages — and a lot of clinic staff — collapse them into a single yes or no. That’s how a technically true sentence leaves you with a false impression.

The four questions:

1. Is the finished product approved? Not the hormone. Not the ingredient. The actual pellet.
2. Is it approved for your population? Men and women are different labels.
3. Is it approved for your condition? Diagnosed hypogonadism in a man isn’t menopause in a woman.
4. Is it the approved product at all — or a compounded one? Different regulatory categories, not different brands.

Run any pellet offer through those four and the fog lifts.

The Testosterone Pellet FDA Status Matrix

Classified against the four questions above. Verified July 15, 2026.

The line that matters: FDA approval attaches to a specific finished product for a specific labeled use. Not to a hormone. Not to a building. Not to a pharmacy license. Not to the word “bioidentical.”

Which testosterone pellet is FDA approved?

Testopel is an FDA-approved testosterone pellet sold in the United States, and its manufacturer describes it as the only FDA-approved testosterone pellet available. Each pellet contains 75 mg of testosterone. Its label lists male indications — specific forms of hypogonadism and certain cases of delayed puberty. Menopause, fatigue, brain fog, and low libido in women are not on it.

Testopel has a strange backstory. According to a peer-reviewed review in Sexual Medicine Reviews (McCullough, 2014), FDA approved fused crystalline testosterone pellets in 1972 — and then nothing happened. The formulation sat unmarketed for decades until a company bought the patent and brought it to market as Testopel in 2008, into a booming men’s testosterone market.

So when a clinic says “there’s an FDA-approved testosterone pellet,” that’s true. It’s Testopel. It’s labeled for men.

The Label Verification Card

Every field is from the current Testopel prescribing information. Check it yourself before you consent to anything.

Read the two “None” rows together. No female indication. No female dosing regimen. It isn’t that a woman is forbidden from receiving Testopel — a clinician can prescribe an approved drug off-label, and that’s normal medicine. It’s that the label offers zero guidance on how to do it. No starting dose. No target. No adjustment schedule. Nothing.

Which brings us to the question that actually matters, and it’s not the one you came in with. The question isn’t how many milligrams. It’s what shape does the release curve make — and can anyone predict where you’ll land on it? Turns out somebody measured that. The answer is in the data below.

Is any testosterone FDA approved for women?

No. FDA has never approved a testosterone product for women in the United States, and none is approved today. Two serious attempts failed: the Intrinsa patch was rejected by a unanimous FDA advisory panel vote in December 2004 over unresolved long-term safety concerns, and BioSante’s LibiGel failed its Phase III efficacy endpoints in 2011. Australia’s regulator approved AndroFeme 1 for women in November 2020. That has no effect in the U.S.

This is the fact the whole page turns on. FDA’s own testosterone information page states that approved testosterone products are approved for use in men who have low testosterone plus an associated medical condition— not men who simply feel tired. Certainly not women.

So in routine U.S. clinical care, a woman on testosterone is in one of two categories:

• An FDA-approved male product, used off-label at a fraction of the male dose, or
• A compounded preparation, which is not an FDA-approved product.

That’s it. Not at any price. Not at any clinic. If someone implies their pellet carries an FDA blessing you couldn’t get elsewhere — that blessing doesn’t exist.

Why the gap?

Two different walls, and they’re worth separating because people get this wrong constantly:

• Intrinsa (2004) wasn’t rejected because it didn’t work. It worked. The advisory committee voted unanimously against approval over unresolved long-term cardiovascular and breast-cancer questions, weighed against a benefit measured at roughly one additional satisfying sexual event.
• LibiGel (2011) was different. It failed on efficacy — the placebo group improved almost as much as the drug group.

One died on safety uncertainty. One died on the numbers. Neither is a conspiracy. Both are why there’s still nothing on the shelf. Meanwhile Australia has an approved product for women. The U.S. gap is a real inequity. That still doesn’t make an implant the answer.

What does “off-label” actually mean here?

Off-label means an FDA-approved drug is used for a population, condition, or dose outside its approved labeling. Clinicians may generally prescribe approved drugs off-label when they judge it appropriate — it’s legal and common. But off-label is not the same as compounded. Actual Testopel in a woman is an approved product used outside its label. A compounded pellet is not an approved product at all. Clinics use “off-label” for both, and that’s where women get lost.

This distinction is the single most useful thing on this page, so let’s be slow about it.

Both are legal. They are not the same thing, and a clinic saying “we use it off-label” might mean either one. Most staff genuinely don’t know the difference. But you need to, because it changes what you’re able to verify. With Testopel, you can pull the label. With a compounded pellet, there’s no label to pull.

If the answer is compounded, your next question is the pharmacy and the lot number. Here’s why that matters more than it did a year ago.

Are compounded testosterone pellets FDA approved?

No. FDA does not approve compounded drugs — it did not approve the finished pellet or verify its safety, effectiveness, or quality before marketing. That’s true whether it came from a 503A pharmacy or a 503B outsourcing facility, and regardless of the brand name on the clinic door. Biote is a practitioner platform, not an FDA-approved drug — and since March 2024 it has owned the 503B facility that makes most of its pellets.

What Biote actually is — and what changed

For years the accurate description was that Biote trains and certifies clinicians in a method and doesn’t touch the pellets. That’s no longer true.

Per Biote’s SEC filings: on March 18, 2024, Biote acquired Asteria Health, a 503B outsourcing facility. Asteria now manufactures a majority of the compounded pellets used by Biote-certified practitioners. Other named Biote 503B facilities include AnazaoHealth and Carie Boyd’s Prescription Shop. The company reports more than 9,200 practitioners across more than 5,300 clinicsas of December 31, 2025. It’s publicly traded as NASDAQ: BTMD.

So Biote is now both the platform andthe manufacturer. The company that trains your clinician also makes your pellet, and that’s worth knowing when you’re evaluating who’s checking whom.

The Biote Regulatory Timeline

Company statements, FDA records, and our conclusions kept separate. Verified July 15, 2026.

On the 4,202: those are records, not 4,202 proven drug-caused injuries. An adverse event report never proves causation. But the records weren’t exonerated either — FDA simply couldn’t attribute them because the information wasn’t there. They had accumulated from 2013 to 2018 in a company portal and were never sent to FDA or to the facilities that made the pellets. The scandal isn’t the number. It’s that nobody could tell.

On Donovitz’s 2019 statement: keep this narrow. He described his own practice at one session. It does not describe every current Biote facility or Asteria’s present quality program. But the release rate isthe product — a pellet’s entire premise is controlled release over months. That the founder of the largest pellet network in America told a National Academies panel his practice didn’t measure it is, in our editorial view, the most revealing sentence in this whole story.

The fair counterpoint:the 2020 NASEM report has been challenged. The Pharmacy Compounding Foundation commissioned a non-peer-reviewed white paper from the Berkeley Research Group arguing the FDA-commissioned report wasn’t independent. It’s industry-funded and it isn’t peer-reviewed. It’s also real, documented, and on the record. We’d rather you hear it from us than find it later and wonder what else we skipped.

What testosterone pellets actually do to your level

Published studies consistently report that testosterone pellets push women’s blood testosterone above the physiologic female range in the weeks after insertion, with wide and unpredictable variation between women. ACOG cites 20–80 ng/dL as a physiologic premenopausal range. Reported measurements in women after pellet insertion include roughly 299 ng/dL at week four and about 256 ng/dL at one month.

The yardstick first. ng/dL means nanograms per deciliter — the unit labs use for testosterone in blood. ACOG’s 2023 clinical consensus cites a physiologic premenopausal range of 20–80 ng/dL. A 2025 review puts postmenopausal women at roughly 10–55 ng/dL using LC-MS/MS. We’ll use ACOG’s 20–80 throughout for consistency. Lab ranges vary by assay and age — your lab’s range is the one that applies to you.

Selected published measurements in women

Not a systematic review. These are studies with extractable numbers we could locate and read. Compiled July 15, 2026.

The number that matters

Look at row one again. 299 ng/dL at week four came from a paper written to defend pellets. The title is “Testosterone implants in women: Pharmacological dosing for a physiologic effect.”That title is an argument. And the data inside it shows women averaging 299 ng/dL a month after insertion — roughly where many labs put the bottom of the adult male reference range.

Now the part that should actually worry you. That study reported a coefficient of variation of 35.9% at week four and 42.6% when symptoms returned. Translation: the spread was enormous. And this was individualized dosing— mean 133.3 mg, ranging from 55 mg to 240 mg. Clinicians were already trying to tailor it. Women still landed all over the map.

That’s the mechanism. It was never about total milligrams. It’s the shape of the release curve— a front-loaded surge, then a long taper — and the fact that nobody can predict which curve you’ll get until you’re already on it. Which is exactly what the founder of the biggest pellet company told the National Academies his practice doesn’t measure.

The honest summary: the evidence leans hard in one direction, but it is not unanimous, and the whole literature is thin. That 2025 review found one randomized controlled trialacross 38 studies. One. For a treatment sold to hundreds of thousands of American women at several hundred dollars a visit. That’s not a conspiracy. It’s a thin evidence base being marketed like a thick one.

What clinics promise vs. what the research found

Pellet clinics commonly market testosterone for energy, muscle, mood, bone density, and mental clarity. The 2019 Global Consensus Position Statement — endorsed by 11 medical organizations — found no benefit for wellbeing, no benefit for depressed mood, and no effect on bone density, lean body mass, body fat, or muscle strength. The one benefit with strong evidence was sexual function in postmenopausal women diagnosed with HSDD.

Sixteen researchers from eleven organizations met in Berlin in May 2019, drew on systematic reviews and meta-analyses of randomized trial evidence, and issued graded recommendations. Level I / Grade A is their strongest rating.

Read that last row twice. The one thing testosterone is actually proven to do for women — the only evidence-based indication the statement recognizes — averages roughly one more satisfying sexual event per month. That’s the real effect size. It’s a genuine benefit and it matters to plenty of women. It’s also nothing like what’s being sold.

Then comes the sentence that ends the argument. Recommendation 4(c) states that the efficacy findings above do not apply to injectables, pellets, formulations producing supraphysiological levels, or compounded preparations.

So the pellet you were offered isn’t just outside the label. It’s outside the evidence the entire field rests on. The trials proving testosterone works in women weren’t done with pellets — and the panel said so deliberately.

Why the guidelines single out this route

The 2019 Global Consensus Position Statement, endorsed by 11 medical organizations, recommends against any testosterone preparation producing supraphysiologic concentrations in women — naming pellets and injections specifically. ACOG’s 2023 Clinical Consensus separately recommends preparations other than pellets, citing limited safety data and inability to remove the pellet. ISSWSH’s guideline says implants may produce supraphysiological levels, don’t allow dose titration, and are not recommended.

This isn’t one skeptical doctor. It’s one consensus statement endorsed by eleven organizations, plus ACOG and ISSWSH reaching similar conclusions separately in their own documents, for their own stated reasons.

The Guideline Scope Matrix

Four documents. Four independent routes to the same conclusion. They don’t all say it for identical reasons — ACOG leads with removal and safety data; the Global Consensus leads with supraphysiologic levels; ISSWSH leads with titration. That convergence from different angles is what makes it hard to wave off.

What the FDA did not do

FDA has not added pellets to any list prohibiting compounding. NASEM recommended in 2020 that FDA consider pellet dosage forms for its “demonstrable difficulties for compounding” list. FDA’s proposed rule, published March 20, 2024, named three categories — none of them pellets. That is narrow, though: it doesn’t mean FDA has taken no action involving pellet compounders. It has.

You’ll find articles claiming that “in 2020, the FDA listed estradiol and testosterone pellets on its list of drugs that present demonstrable difficulties for compounding.” That claim is false. The actual sequence:

But here’s the limit of that correction. “Not on the difficult-to-compound list” is not the same as “FDA has taken no action.” FDA maintains a public list of compounding inspections, recalls, and actions — and Asteria Health, Biote’s own 503B facility, appears on it with a Form 483 issued December 19, 2025. The January 2026 lot recall happened with FDA’s knowledge. FDA is very much still inspecting.

We’re including this because it’s true and a lot of pages get it wrong. We’d rather be right than persuasive. If we’ll correct a claim that helps our argument, you can trust the ones that don’t.

“But my clinic said it’s FDA-approved”

Clinics frequently use accurate-sounding phrases that don’t establish what you think they establish. “FDA-approved ingredients,” “FDA-registered facility,” and “FDA-regulated” are all statements about something other than the finished pellet’s approval status. One question resolves it: is this exact finished product FDA-approved for this exact use?

You’re not being paranoid. This language is everywhere, and it usually isn’t a deliberate lie — most staff genuinely don’t know the difference.

The FDA Claim Translator

A good clinic answers that clearly and puts it in writing. That’s the standard. Not how fast they answer — whether they’ll write it down.

Can a testosterone pellet be removed?

The Testopel label contemplates removal when complications require testosterone’s effects to be discontinued — so “pellets can never be removed” overstates it. But removal is an in-person procedure, it may not give immediate or complete reversal, and it is not a routine way to adjust a dose. ACOG cites inability to remove the pellet as a reason to prefer other preparations.

Against the pellet critics:you’ll read constantly that pellets “cannot be removed.” That’s not what the label says. Testopel’s prescribing information states pellets would have to be removed when complications require discontinuing testosterone’s effects. Removal is contemplated. It’s real.

Against the pellet clinics:contemplated isn’t routine. Removal requires an in-person procedure and may not provide immediate or complete reversal. Nobody schedules it casually. And the product was never designed to come out — that’s the entire premise.

The Reversibility Matrix

Based on route properties only.

Dr. Jick at Cedars-Sinai put the clinical version plainly: if levels come back higher than expected, you can’t adjust the dosing or remove the medication — which is why many clinicians prefer topicals.

Two more things the Testopel label lists in postmarketing reports: implantation site infection and pellet extrusion— the pellet working its way back out through your skin.

What should I ask before getting testosterone pellets?

A responsible consultation should produce clear written answers about the exact product, its approval status, the pharmacy and lot, the indication, the evidence, the monitoring plan, alternatives, cost, and what happens if it doesn’t suit you. A verbal assurance that a pellet is “natural,” “bioidentical,” or “FDA-regulated” is not an answer to any of those.

The eight questions

Take these with you. Ask for the answers in writing.

1. 1

   Is this actual Testopel, or a compounded pellet?

2. 2

   Is the finished pellet FDA-approved — yes or no?

3. 3

   Which pharmacy or facility made it? Is it 503A or 503B?

4. 4

   What's the lot number — and has that lot been recalled?

   This one has a real answer since January 2026.

5. 5

   What's the exact strength, and how many pellets?

6. 6

   What condition are you treating, and what evidence supports pellets for it in women?

   If the answer is energy, mood, or brain fog — those aren't evidence-based indications.

7. 7

   When will my testosterone be checked — baseline, 3–6 weeks, then every 6 months?

   This is the Global Consensus schedule. If nobody plans to monitor, ask why.

8. 8

   If my level comes back above your target, what exactly happens next?

Plus the money question, which somehow never makes it into the brochure: what’s the total annual cost, including labs, visits, and reinsertions?

Don’t consent until all eight are answered clearly and in writing.Not because a slow answer proves misconduct — sometimes it’s just an admin gap. But this is an implant. You get to have it in writing first.

Question 7 has a right answer, and it’s not ours — it’s the Global Consensus schedule: a baseline level before you start, a repeat at 3–6 weeks, then every 6 months to screen for overuse. If nobody plans to measure you, ask why.

If not pellets, then what?

Because no FDA-approved testosterone exists for women, every testosterone option is either an approved male product used off-label or a compounded preparation. Guidelines point to adjustable transdermal testosterone — a cream or gel you can titrate — rather than implants. But testosterone is the right target for a narrow problem, and for most menopause symptoms the better answer is an FDA-approved estrogen product.

First, the most useful question: what are you actually trying to fix?

One thing to check before you assume: a pellet may contain estradiol as well as testosterone.Ask which hormones are in it and what each one is meant to treat. “Pellet” isn’t a hormone.

If you’re in rows 1, 2, 4, 5, 6, or 7 — testosterone isn’t the medication you’re looking for. Read our guide on FDA-approved HRT options and how to choose a routeinstead. We’d rather lose you to the right page than keep you on the wrong one.

The damaging admission

We’re about to recommend Midi Health. So here’s what should bother you about that, said before we say anything nice:

Midi’s testosterone is compounded. It is not FDA-approved.Their own materials describe it as compounded testosterone therapy. On a page about FDA approval, our recommendation isn’t FDA-approved either. Nobody’s is. It doesn’t exist. That was the whole first half of this page.

So if an FDA-approved label is your hard requirement — genuinely, no compromise — then the honest answer is that testosterone is not your path, and you should be looking at FDA-approved estradiol and progesterone instead. Start here. We mean it. Go.

But if you’re staying, be clear about what you’re actually deciding. There are two separate questions, not one:

• The product question: approved product used off-label, versus a compounded product. This one you cannot solve. There is no approved female testosterone. Every road here is off-label or compounded. That doesn’t go away because it’s inconvenient.
• The route question: can you adjust it, or are you committed for months? You can absolutely win this one — and it’s the one every guideline actually talks about.

Midi: what they say vs. what we verified

Provider statements separated from independent findings. Verified July 15, 2026 — programs change, confirm at intake.

Now put the money side by side, because nobody else will. Pellets run several hundred dollars per insertion, two to four times a year, and are commonly excluded from coverage. Midi’s cream starts at $100 for 90 days, with visits that may run through your PPO.

You’re not paying a premium for the irreversible option. You’re paying more for it.

On Medicaid or Medi-Cal? Midi won’t take you, even cash. That’s a real dead end — Find My HRT Path will route you to what actually works in your situation.

One thing we won’t do: Winona is one of our affiliate partners. They don’t prescribe testosterone — they offer DHEA, a testosterone precursor. The same Global Consensus we’ve cited all page says systemic DHEA cannot be recommendedfor HSDD, at Level IA, Grade A. So we’re not sending you there for this. If we did, this page would be arguing against itself.

Does insurance cover testosterone pellets for women?

Coverage is plan-specific, and off-label status alone doesn’t automatically kill it. But several payers classify hormone pellet implantation for menopause symptoms as investigational and don’t cover it, and compounded products are commonly excluded outright. Verify the exact product, diagnosis, procedure code, and compounding exclusion with your own plan before you pay.

“No FDA-approved indication means no coverage” sounds airtight. It isn’t true. Off-label drugs get covered all the time — oncology runs on off-label prescribing. Coverage is decided by benefit design and plan policy, not by a syllogism. What is true is narrower:

That last row is the pattern most women hit: labs and visits sometimes covered, pellets usually not.

On CPT 11980:that’s the billing code for subcutaneous hormone pellet implantation. A code is not coverage. It identifies a procedure — it doesn’t establish medical necessity, eligibility, or that your plan pays for it. If a clinic waves the code at you as evidence of coverage, that’s not what it means.

What to actually do:call your plan with the exact product name, the diagnosis code, and CPT 11980, and ask three questions — is the product covered, is the procedure covered, and is there a compounded-drug exclusion? Those can have three different answers.

If you already have pellets

This page cannot tell you whether your situation is urgent — that takes a clinician who has your chart and your labs. What it can do is help you assemble the facts you’re entitled to. If you have symptoms of an infected insertion site, unexplained bleeding, or voice changes, contact your prescriber promptly.

We’ve been hard on this route. Let’s be careful with you specifically. You didn’t do anything wrong.You made a decision based on the information you were given. That’s what everyone does. Here’s what’s worth doing, in order:

1. 1
   Find out what you got. Product, strength, number of pellets, pharmacy or facility, lot number, insertion date. If your pellets came from Asteria Health, the January 2026 recall was lot-specific — ask the clinic to check your lot. Not to alarm you. Because you're entitled to the answer and it takes them thirty seconds.
2. 2
   Find out your number. Ask for your total testosterone from after your last insertion. If nobody drew it, that's the gap to close — not because you're in danger, but because you're currently flying without instruments.
3. 3
   Read it against the right range. Compare the result to your lab's reference range and your clinician's stated target. ACOG cites 20–80 ng/dL as one physiologic premenopausal range. A result above the intended range is worth a prompt conversation about monitoring — with them, not a webpage.
4. 4
   Notice what your body's been saying. Acne, oily skin, new facial or body hair, scalp thinning, mood changes, irritability. If those started after an insertion, that's information, not vanity.
5. 5
   Know what needs a call today. Voice deepening can be permanent — that warrants a prompt call, not wait-and-see. Same with an insertion site that's red, hot, painful, or draining, and any abnormal uterine bleeding.
6. 6
   You can decline the next one. Declining a reinsertion stops future dosing — but the implant you have keeps releasing until it's done. Plan the timing, monitoring, and any transition with your prescriber rather than just not rebooking.

On that last point, one more piece of data, with its limitations attached. The Jiang retrospective compared unmatched treatment cohorts with materially different hormone exposure. Within that limitation: abnormal uterine bleeding was recorded in 55.3% of pellet users with an intact uterus versus 15.2% on FDA-approved therapy, and hysterectomy following that bleeding in 20.3%versus 6.3%. It’s a flawed comparison and we’ve said so. But if you have a uterus and you’re bleeding on pellets, that’s a reason to be seen — not a reason to wait it out.

You’re not in trouble. You’re entitled to your own numbers.

When online care isn’t the right starting point

Some situations need a clinician in the room. An insertion site that looks infected, a pellet extruding, unexplained bleeding, severe or rapidly worsening symptoms, wanting a pellet removed, or a complex history involving breast cancer, blood clots, cardiovascular disease, or liver disease — those start in person.

• An insertion site that’s red, hot, swollen, painful, or draining. Call the prescriber today.
• A pellet coming out through the skin. Extrusion is in the label’s postmarketing reports. It needs a clinician.
• Unexplained bleeding. Needs an exam.
• You want it out. That’s a procedure.
• Severe or fast-worsening anything. Urgent care or the ER, not a website.
• A history of breast cancer, blood clots, stroke, heart disease, or liver disease. Hormone decisions here need someone with your whole chart.
• Pregnant or possibly pregnant.

This isn’t a complete list of who shouldn’t use hormone therapy — that’s a conversation, not a checklist. The HRT Index’s Find My HRT Path tool flags these too — it’ll tell you when to skip online care entirely.

How we verified this page

The HRT Index Editorial Teamchecked the current Testopel prescribing information, FDA’s testosterone information page, FDA’s 2019 statement on compounded drug adverse event reporting, FDA’s compounding and outsourcing facility guidance, FDA’s compounding actions list, the 2024 proposed rule on demonstrable difficulties for compounding, the 2019 Global Consensus Position Statement, ACOG Clinical Consensus No. 6, the 2020 NASEM report, Biote’s SEC filings including the January 2026 recall disclosure, payer policies, and the pellet studies cited above. This is editorial research under The HRT Index Verification Standard. It is not a clinical guideline.

Last verified: July 15, 2026 — read the methodology

The source log

Corrections we made to our own earlier draft

• We removed a dose calculation that compared milligram content of an implant to a daily topical dose. Those aren’t the same unit, and the comparison doesn’t hold. It was our own original analysis and it was wrong.
• We corrected our description of Biote’s business, which was based on an older filing and missed the March 2024 Asteria acquisition.
• We corrected our insurance section, which claimed off-label status universally prevents coverage. It doesn’t.
• We corrected a claim about controlled-substance refills that stated a provider’s policy as if it were federal law.
• We demoted the Jiang comparison after finding only 16 women in the comparison cohort had testosterone values.
• We removed a study we had counted as independent corroboration — it was an earlier presentation of the same study line.

Found something outdated or wrong? Tell us. We publish corrections. You just read six of them.

Frequently asked questions

Is Testopel FDA approved?

Yes. Testopel is an FDA-approved 75 mg testosterone pellet, supplied as an unscored implant. Its label lists male indications — specific forms of hypogonadism and certain delayed puberty cases. It’s a Schedule III controlled substance.

Is Testopel FDA approved for women?

No. The label has no female indication and gives no female dosing regimen. A clinician can prescribe it off-label, which is legal — but the label offers no guidance on how, so there’s no approved starting dose, target, or adjustment schedule to work from.

Are Biote pellets FDA approved?

No. Biote is a practitioner training and platform company, not an FDA-approved drug. Its pellets are compounded — a majority by Asteria Health, the 503B facility Biote has owned since March 2024. Compounded finished products are not FDA-approved. Ask for the product, strength, facility, and lot number in writing.

Were Biote pellets recalled?

Some lots. On January 26, 2026, Biote disclosed that Asteria Health voluntarily recalled specified hormone pellet lots shipped between May 20, 2025 and January 2026 over possible metal particulate. It was lot-specific, not a recall of every pellet. If your paperwork names Asteria, ask your clinic to check your lot against the recall.

Are compounded testosterone pellets FDA approved?

No. FDA did not approve the finished compounded pellet or verify its safety, effectiveness, or quality before marketing. That’s true for both 503A pharmacies and 503B outsourcing facilities.

Does “FDA-approved ingredients” mean the pellet is FDA approved?

No. An ingredient claim says nothing about whether the finished pellet — that strength, made that way, for your use — has been approved. Ask: “Is the finished pellet FDA-approved?”

Does an FDA-registered pharmacy mean the pellet is approved?

No. FDA states that registering as an outsourcing facility doesn’t mean the facility makes FDA-approved drugs, or that FDA has found it compliant. Registration is about the building. Approval is about the drug.

Is off-label testosterone prescribing legal?

Generally yes. Clinicians may prescribe approved drugs for unapproved uses when they judge it appropriate. That’s normal medicine. But off-label means FDA hasn’t determined that use is safe and effective — and it’s not the same as compounded. Testosterone is Schedule III and requires a valid prescription from a licensed prescriber.

Do I need a new appointment for every testosterone refill?

Not necessarily under federal law. Schedule III prescriptions may generally be refilled up to five times within six months of the date written; after that, a new prescription is required. Whether you need a new visit depends on your prescriber, your state’s law, and telemedicine rules — not on a single federal rule.

Can testosterone pellets be removed?

Sometimes. The Testopel label says pellets would have to be removed if complications require discontinuing testosterone’s effects. But it’s an in-person procedure, may not give immediate or complete reversal, and isn’t a routine way to adjust a dose. ACOG cites inability to remove the pellet as a reason to prefer other preparations.

Are testosterone pellets safe for women?

The honest answer is that the evidence isn’t strong enough to say confidently either way — and that’s the problem. A 2025 structured review found one randomized controlled trial across 38 studies. Documented concerns include supraphysiologic early levels, wide unpredictability between women, inability to adjust, insertion site infection, and extrusion. Discuss it with a clinician who knows your history. See also: our full guide on testosterone pellet safety.

Are testosterone pellets covered by insurance for women?

Usually not, but it’s plan-specific. Several payers classify hormone pellet implantation for menopause symptoms as investigational, and compounded products are commonly excluded as a category. Labs and office visits are often adjudicated separately. Verify the product, diagnosis, procedure code, and compounding exclusion with your plan.

Does “bioidentical” mean FDA approved?

No. Bioidentical describes molecular structure — it isn’t an FDA category. Many FDA-approved hormone products are bioidentical, including estradiol patches and micronized progesterone. The word tells you nothing about approval status.

Has the FDA banned hormone pellets?

No. NASEM recommended in 2020 that FDA consider pellet dosage forms for its difficult-to-compound list. FDA’s March 2024 proposed rule named three categories and pellets weren’t among them. That said, “not on that list” isn’t “no FDA action” — FDA inspects compounders, and issued Form 483 observations to Biote’s Asteria Health facility in December 2025.

What’s the difference between a 503A pharmacy and a 503B facility?

A 503A is a state-licensed pharmacy compounding against a prescription for a named patient. A 503B is an FDA-registered outsourcing facility that can make office stock and must follow manufacturing standards. Neither one’s finished product is FDA-approved.

Does the FDA’s 2026 boxed warning change apply to my pellets?

No. FDA approved boxed-warning changes for an initial six menopausal hormone therapy products on February 12, 2026, removing cardiovascular, breast cancer, and probable dementia language. Compounded pellets have no FDA label, so there’s nothing to update — the change doesn’t reach them either way, and it doesn’t determine what’s right for any individual.

What should be on my paperwork before insertion?

Product name, strength per pellet, number of pellets, manufacturer or compounding pharmacy, 503A or 503B, lot number, whether it’s compounded, the condition being treated, total cost, and the monitoring plan. “It’s FDA-regulated” is not paperwork.

Related pages

• Are testosterone pellets safe for women? (guidelines & risks)
• Pellet therapy side effects women report (what’s urgent, what lasts)
• Are hormone pellets safe? What ACOG, the FDA & NAMS say
• Hormone pellets vs patch: compare FDA status, reversibility, and cost
• Testosterone pellets vs cream for women: side-by-side comparison
• Hormone pellet therapy cost 2026: real prices and hidden fees
• FDA-approved HRT options: how to choose the right route